LCTX

#2787
Lineage Cell Therapeutics, Inc. Common Stock
1.3 4 USD
+9900.00%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
1.34
1.35
Faixa anual
0.01
1.98
Mudança diária
+9900.00%
Mudança mensal
-10.65%
Mudança em 6 meses
-21.96%
Mudança anual
-21.96%
Fechamento anterior
0.0 1
Open
1.3 5
Mínimo
1.3 4
High
1.3 5
Volume
19
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
Demonstração de resultados Balanço patrimonial Fluxo de caixa
Valor 202020212022202320242025

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.

Notícias